1Das A.Cost-effectiveness of different strategies of cytomeg alovirus prophylaxis in orthotopic liver transplant recipients[J].Hepatology,2000,31(2): 311-317.
2Torres A,Ewig S,Insausti J,et al.Etiology and microbial patterns of pulmonary infiltrates in patients wit h orthotopic liver transplantation[J].Chest,2000,117(2): 494-502.
3Singh N,Chang FY,Gayowski T,et al.Fever in liver transpla nt recipients in the intensive care unit[J].Clin Transplant,1999,13(6): 504 -511.
4Lohmann R,Langrehr JM,Klupp J,et al.Infect ious complications after orthotopic liver transplantation with different immunos uppressive induction regimens[J].Transplant Proc,2000,32: 537-538.
5Malkan G,Cattral MS,Humar A,et al.Lamivudine for hepati tis B in liver transplantation: a single-center experience[J].Transplantatio n,2000,69(7): 1403-1407.
6Keeffe EB.End-stage liv er disease and liver transplantation: role of lamivudine therapy in patients wit h chronic hepatitis B[J].J Med Virol,2000,61(3): 403-408.
2Polson J, Lee WM. American Association for the Study of Liver Diseases (AASLD) position paper: the management of acute liver failure [ J ]. Hepatology,2005,41 (5) : 1179 - 1197.
3Abouna GM, Ganguly PK, Hamdy HM, et al. Extracorporeal liver perfusion system for successful hepatic support pending liver regeneration or liver transplantation [ J ]. Transplantation, 1999,67 (12) :1576 - 1583.
4De Silvestro G, Marson P, Brandolese R, et al. A single institution's experience ( 1982 - 1999 ) with plasma-exchange therapy in patients with fulminant hepatic failure [ J ]. Int J Artif Organs, 2000,23(7) :454-461.
5Farmer DG, Anselmo DM, Ghobrial RM, et al. Liver tansplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period [ J ]. Ann Surg, 2003,237 ( 5 ) : 666 - 675.
6Bismuth H, Samuel D, Castaing D, et al. Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience [ J ]. Ann Surg, 1995,222 (2) : 109 - 119.
